Featured Research

from universities, journals, and other organizations

Promising target found in treating deadly brain cancer

Date:
July 1, 2013
Source:
National Cancer Institute (NCI) at NIH
Summary:
Researchers have identified a promising target for treating glioblastoma, one that appears to avoid many of the obstacles that typically frustrate efforts to develop effective treatments for this deadliest of cancers.

Researchers at the University of Virginia Cancer Center have identified a promising target for treating glioblastoma, one that appears to avoid many of the obstacles that typically frustrate efforts to develop effective treatments for this deadliest of cancers.

Related Articles


Glioblastomas are the most common form of brain tumor in adults -- and the most aggressive. Because of the way the tumors invasively infiltrate the brain, spreading like ivy, they cannot be removed fully by surgery. There is no cure, and few patients survive more than two to three years even with aggressive treatment.

The UVA researchers, however, have identified a potential target they believe is essential to the glioblastoma cells. This vital enzyme, they believe, regulates cancer cell survival, proliferation, and tumor formation. Inhibit the enzyme, their work suggests, and the cancer cell dies.

"This is an exciting new target in cancer," said UVA's Benjamin W. Purow, MD. "It seems to have potential not just for brain tumors but for other cancers as well. We think it has activity on its own, but also in combination with other cancer therapies."

Glioblastoma, melanoma

Glioblastoma is difficult to treat because it is persistent, aggressive and resourceful. Efforts to block its pathways are often unsuccessful because the cancer simply uses others. That has researchers looking for ways to inhibit multiple pathways at once, or targeting critical signaling nodes that control multiple pathways.

"We're finding that we're not having a lot of luck, often, when we just inhibit a single target in cancer cells, so we're really interested in finding targets specific targets that control many pathways to cancer," Purow explained. And he thinks he's found one: Diacylglycerol kinase alpha. By targeting this lipid-modifying enzyme, the UVA researchers believe, they can inhibit and kill glioblastoma cells and other forms of cancer, such as melanoma.

A drug in hand

Promisingly, the researchers already have identified a drug that targets the enzyme. The federal Food and Drug Administration has not yet approved its use, but previous tests, when it was being evaluated for other purposes, have suggested the compound is safe for use in people.

"We think we have at least an initial way into patients," Purow said. "We may ultimately want to come up with more powerful inhibitors, or more targeted inhibitors of DGKα, and I think those will be some future directions -- but there are a lot of exciting ways we're going with this."

Developing new treatments

For now, the UVA researchers will continue to explore their new discovery, investigating it further and ensuring safety before testing it in humans. But they have a drug compound in hand should speed the process, Purow said. "I'm hoping we can start doing phase I trials in people within a couple of years," he said. "I think that's a realistic time frame. I'd couch that by saying that's our goal -- but we think that's feasible."

Purow emphasized that the UVA discovery isn't a cure for glioblastoma or other cancers. But he said it might prove to be a formidable new "tool in the toolbox" to complement existing treatments such as surgery, radiation and chemotherapy.

"We're optimistic that this may have an impact on cancer course and may help sensitize to other treatments as well," Purow said. "I hope it can make a difference for people."


Story Source:

The above story is based on materials provided by National Cancer Institute (NCI) at NIH. Note: Materials may be edited for content and length.


Journal Reference:

  1. C. L. Dominguez, D. H. Floyd, A. Xiao, G. R. Mullins, B. A. Kefas, W. Xin, M. N. Yacur, R. Abounader, J. K. Lee, G. M. Wilson, T. E. Harris, B. W. Purow. Diacylglycerol Kinase   Is a Critical Signaling Node and Novel Therapeutic Target in Glioblastoma and Other Cancers. Cancer Discovery, 2013; DOI: 10.1158/2159-8290.CD-12-0215

Cite This Page:

National Cancer Institute (NCI) at NIH. "Promising target found in treating deadly brain cancer." ScienceDaily. ScienceDaily, 1 July 2013. <www.sciencedaily.com/releases/2013/07/130701163741.htm>.
National Cancer Institute (NCI) at NIH. (2013, July 1). Promising target found in treating deadly brain cancer. ScienceDaily. Retrieved March 28, 2015 from www.sciencedaily.com/releases/2013/07/130701163741.htm
National Cancer Institute (NCI) at NIH. "Promising target found in treating deadly brain cancer." ScienceDaily. www.sciencedaily.com/releases/2013/07/130701163741.htm (accessed March 28, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, March 28, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) — A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com
WH Plan to Fight Antibiotic-Resistant Germs

WH Plan to Fight Antibiotic-Resistant Germs

AP (Mar. 27, 2015) — The White House on Friday announced a five-year plan to fight the threat posed by antibiotic-resistant bacteria amid fears that once-treatable germs could become deadly. (March 27) Video provided by AP
Powered by NewsLook.com
House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) — In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins